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Falcipain-2 (FP-2) and falcipain-3 (FP-3), haemoglobin-degrading enzymes in Plasmodium falciparum, are validated
drug targets for the development of effective inhibitors against malaria. However, no commercial drug-targeting falci-
pains has been developed despite their central role in the life cycle of the parasites. In this work, in silico approaches
are used to identify key structural elements that control the binding and selectivity of a diverse set of non-peptidic com-
pounds onto FP-2, FP-3 and homologues from other Plasmodium species as well as human cathepsins. Hotspot residues
and the underlying non-covalent interactions, important for the binding of ligands, are identiﬁed by interaction ﬁngerprint
analysis between the proteases and 2-cyanopyridine derivatives (best hits). It is observed that the size and chemical type
of substituent groups within 2-cyanopyridine derivatives determine the strength of protein–ligand interactions. This
research presents novel results that can further be exploited in the structure-based molecular-guided design of more
potent antimalarial drugs.
Keywords: malaria; homology modelling; docking; molecular dynamics; falcipains
1. Introduction
Malaria is an infectious disease caused by a diverse
group of erythrocytic protozoan parasites of the genus
Plasmodium. It remains an exigent public health problem
in the tropical areas of Africa, South America and parts
of Asia and continues to take its toll in morbidity and
mortality with half of the world’s population under a per-
manent risk of infection leading to more than half a mil-
lion deaths annually (WHO, 2013). Five Plasmodium
species, namely P. falciparum (Pf), P. vivax (Pv), P. ovale
(Po), P. malariae (Pm) and P. knowlesi (Pk), are known
to infect humans with Pf responsible for more than 90%
of the malarial fatalities reported in sub-Saharan Africa.
The predominance of Pf is attributed to its adaptability
(Ashley, McGready, Proux, & Nosten, 2006; Prugnolle
et al., 2011). Although the high occurrence of the Duffy
negative trait among African populations lowers the
threat posed by Pv, it is the most frequent and widely
causative agent of benign tertian malaria in other parts of
the world (Mendis, Sina, Marchesini, & Carter, 2001). In
addition to the listed human malarial parasite forms, sev-
eral other Plasmodium species, which infect non-human
laboratory models, have been identiﬁed and are of signif-
icant importance in understanding the parasite biology,
the host–parasite interactions and in the drug develop-
ment process (Langhorne et al., 2011).
Malaria still remains a major threat primarily due to
the emergence of drug-resistant parasitic mutations, partic-
ularly to available frontline antimalarial drugs, a situation
aggravated by the absence of an effective vaccine that has
remained elusive to date (Hartjes, 2011). In addition, the
recent reports indicating the emergence of resistance to
artemisinin, which is the cornerstone to the current artemi-
sinin-based combination therapies (ACT), emphasizes the
continued need for identiﬁcation of new drugs with novel
scaffolds and mode of action (Mok et al., 2011; Saralamba
et al., 2011). A formidable hurdle against successful elimi-
nation of malaria is the identiﬁcation of a broad range of
drugs targeting common druggable targets in both the
active human forms of Plasmodium and the circulating
wild species. Several Plasmodium drug targets including
but not limited to falcipains (FPs) (Marco & Miguel
Coteron, 2012), serine/threonine protein phosphatase 5,
serine repeat antigens, apicoplast-targeted tRNA-guanine
transglycosylase (Gupta et al., 2015), Pf lactate dehydro-
genase (Thillainayagam et al., 2014) and heat shock
proteins (Hatherley, Blatch, & Tastan Bishop, 2014) have
been identiﬁed. In the current study, our focus is on the
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falcipains that are validated drug targets (Teixeira, Gomes,
& Gomes, 2011).
The FPs are a homologous family of four Pf cysteine
proteases viz. FP-1, FP-2, FP-2′ and FP-3, which are
fairly similar to papain-like human cathepsins but with
eccentric features such as longer prodomains and a 14
amino acid (aa) insert between highly conserved residues
near the C-terminus (Rosenthal, 2011). FP-1 is distantly
related to the other FPs, and its role in the Plasmodium
development process remains unclear (Kumar et al.,
2007). FP-2 and FP-2′ have a ~99% sequence identity
and differ only in three amino acids; none of which is
located in the active-site cavity (Mane et al., 2013).
Through chemical inhibitory studies against FP-2 and
FP-3 as well as FP-2 gene disruption experiments, both
enzymes have been shown to play indispensable roles
either solely or in concert with other proteases, as they
possess a nucleophilic thiolate group in their active site’s
cysteine residue which is key for amide bond cleavage
(Ehmke et al., 2011). These two proteases of the clan
CA family are not only key in the haemoglobin degrada-
tion pathway which is the sole source of amino acids for
the exponential growth and proliferation of the parasites
but also in the erythrocyte egression and rupture process
(Marco & Miguel Coteron, 2012; Rosenthal, 2011).
Several attempts combining chemical synthesis and in
silico screening approaches have been undertaken in the
past decade to discover and optimize inhibitors targeting
parasite proteases of infectious agents, leading to two
broad classes of chemical compounds viz. peptidomimetic
and non-peptidic small molecules. Such attempts have
successfully led to the discovery of several therapies in
other diseases such as those against hepatitis C virus
(HCV) (Melnikova, 2008) and human immunodeﬁciency
virus (HIV) (Flexner, Bate, & Kirkpatrick, 2005). As
reviewed by Mane et al., scientiﬁc efforts to develop FP-
2 and FP-3 inhibitors have mainly realised peptide based
compounds (Mane et al., 2013) such as α-ketoamides
(Lee et al., 2003), peptidyl aldehydes (Rosenthal, Lee, &
Smith, 1993), E-64 epoxysuccinyl derivatives (Schulz
et al., 2007); but none has ever been commercialized as
an antimalarial drug due to inherent poor pharmacological
proﬁles as well as susceptibility to degradation by host
enzymes (Ettari et al., 2010). The identiﬁcation and vali-
dation of small non-peptide FP inhibitors is expected to
overcome these shortcomings, and so far several com-
pounds belonging to isoquinolenes, chalcones and others
(Batra, Sabnis, Rosenthal, & Avery, 2003; Domínguez
et al., 2005; Li et al., 1995; Liu, Wilairat, & Go, 2001)
have been shown to possess antimalarial potency either
on whole Pf parasite cultures or directly on FP-2 protein
at low micromolar ranges. Coteron et al., recently
reported a new class of compounds that belong to the het-
eroaryl nitrile class hitherto vouched as the most potent.
Through a sequential lead optimization process, several
5-substituted-2-cyanopyrimidines derivatives (CPs) with
FP-2 and FP-3 inhibitory potency and anti-plasmodial
activity in the picomolar to low nanomolar ranges were
obtained (Coterón et al., 2010).
To facilitate the discovery of novel potential anti-
malarial compounds, our aim was to set up a reliable
integrated virtual screening workﬂow comprising of
homology modelling, molecular docking, molecular
dynamics (MD) and binding free energy (BFE) calcula-
tions, which can be used to identify potential non-peptide
compounds against plasmodial cysteine proteases. A
diverse set of compounds from the literature with
reported potency against FP-2 and/or FP-3 were used to
determine their mode of interaction with FP-2 and FP-3
and their plasmodial homologues (targets) and their
selectivity towards the human papain-like cathepsins
(off-targets). These compounds are CPs (Coterón et al.,
2010), chalcones (Domínguez et al., 2005; Li et al.,
1995; Liu et al., 2001), isoquinolenes (Batra et al., 2003)
and thiosemicarbazones (Chipeleme, Gut, Rosenthal, &
Chibale, 2007; Chiyanzu et al., 2003; Greenbaum et al.,
2004). After docking, guided by molecular-docking
energy scores, compounds that showed the best scores
were further put through MD simulations and interaction
energy quantiﬁed via BFE calculations. The dynamical
behaviour and strength of interactions of the protein–
compound complexes were analysed to describe the pos-
sible binding modes, the interacting structural elements
as well as the stability of the complexes, information
which may be potentially useful in the drug discovery
and development process of novel broad-spectrum anti-
malarial agents. The key amino acid residues contribut-
ing to different interactions with potential inhibitors were
identiﬁed. Overall, the following observations were
made: (i) there exist amino acid composition differences
in the subsites of plasmodial FP-2 and FP-3 homologues
and human cathepsins, which could be important for
inhibitor design; (ii) out of the four classes of com-
pounds used, the CPs are the best docked inhibitors with
very low BFEs against plasmodial proteases compared
to human cathepsins, thus showing a degree of selectiv-
ity; (iii) The substituent chemical groups in the main
CPs scaffold determine the overall potency of the indi-
vidual derivatives.
2. Methods and materials
The ﬂow diagram of the methodology followed in this
study is presented in Figure 1 and the details are given
below.
2.1. Sequence retrieval
FP-2 and FP-3 protein sequences (accession numbers:
PF3D7_1115700 and PF3D7_1115400, respectively)
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were retrieved from PlasmoDB version 9.3 (Aur-
recoechea et al., 2009) and used as queries to retrieve
homologue sequences of other Plasmodium species and
humans using the BLASTP tool in the PlasmoDB and
the NCBI database (Sayers et al., 2009), respectively. To
conﬁrm whether the retrieved hits were the true ortho-
logues, reverse BLAST searches were performed. Only
sequences with signiﬁcant query coverage, E-values
lower than 1.0 × 10−5 were selected (Text S1). Crystal
structures of the human cathepsins (Cat K [PDB ID:
3OVZ], Cat L [PDB ID: 3OF8], Cat S [PDB ID: 1NPZ]
together with those of FP-2 [PDB ID: 2OUL] and FP-3
[PDB ID: 3BWK] were retrieved from the Brookhaven
Protein Data Bank (PDB) (Bernstein et al., 1977).
2.2. Multiple sequence alignment
Multiple sequence alignment (MSA) was done using
web-based servers, namely MAFFT (Katoh, Misawa,
Kuma, & Miyata, 2002) and PROMALS3D (Pei, Kim,
& Grishin, 2008) and alignment outputs compared to
determine the alignment accuracy. For MAFFT program,
the following sequence alignment parameters were uti-
lized; substitution matrix was set as BLOSUM62 scoring
matrix (Eddy, 2004), gap opening and extension
penalty of 1.53 and .123, respectively. The number of
tree-building steps was adjusted to 2 with maximum iter-
ation set at 2. For PROMALS3D, structural information
from the crystal structures of FP-2 and FP-3 was added
to guide the alignment using default parameters with an
exception of PSI-BLAST expect value which was
adjusted to .0001. Alignment parameter for sequences
within groups in the ﬁrst alignment stage was set to the
slow but more accurate PROMALS algorithm (Jimin Pei
& Grishin, 2007). The initial alignment was done for the
full-length protein sequences and trimmed using JalView
software (Waterhouse, Procter, Martin, Clamp, & Barton,
2009) to obtain the catalytic domain portions of the
cysteine proteases that were realigned. From the MSA,
sequence identities, similarities and conserved regions
were identiﬁed. Subsite residues were extracted from the
alignment into a Fasta ﬁle and submitted to WebLogo
(Crooks, Hon, Chandonia, & Brenner, 2004), a web-
based sequence logo generator, to determine the residue
conservation at these speciﬁc positions in a WebLogo
presentation.
2.3. Homology modelling
For each of the FP-2 and FP-3 plasmodial homologues,
the HHpred web server (Soding, Biegert, & Lupas,
2005) was utilized to search for suitable templates for
Figure 1. Graphical workﬂow for identiﬁcation of FP-2/3 homologues (sequence and structure) and analysis of non-peptidic com-
pounds as potential inhibitors via in silico approaches. Bold and in brackets are the key databases, web servers and tools used.
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building high-quality models to be used in the subse-
quent docking and molecular dynamics steps. Selection
of predicted templates was based on the one with the
highest sequence identity, coverage and resolution. Two
templates were retrieved from PDB, namely [PDB ID:
2OUL] (Wang et al., 2007) and [PDB ID: 3BWK] (Kerr,
Lee, Farady et al., 2009) for FP-2 and FP-3, respectively.
Template quality validation was performed using
MetaMQAPII (Benkert, Biasini, & Schwede, 2011),
ANOLEA (Melo, Devos, Depiereux, & Feytmans,
1997), QMEAN (Benkert, Tosatto, & Schomburg, 2008)
and PROCHECK (Laskowski, MacArthur, Moss, &
Thornton, 1993). Manual adjustments were made in the
template-target alignment ﬁles where applicable by com-
paring the HHpred and PROMALS3D structural align-
ment output with that of MAFFT. For each homologue,
200 models were calculated using MODELLER version
9.10. Models were ranked using DOPE Z scores (Shen
& Sali, 2006). The top three models with the lowest
energy scores for each protein were further validated by
MetaMQAPII and PROCHECK. Disulphide bond forma-
tions in the models were assessed through Protein Inter-
action Calculator (PIC) web server (Tina, Bhadra, &
Srinivasan, 2007) in relation to the FP-2 and FP-3 tem-
plates. The top best model for each protein was selected
for the subsequent steps of molecular docking and
molecular dynamics.
2.4. Compounds
All the compounds (CPs, chalcones, isoquinolenes,
thiosemicarbazones) and associated activity data used in
this study were retrieved from published data. In DS
(Discovery Studio version 3.1, Accelrys Software Inc.
Discovery Studio Modelling Environment, San Diego:
2011), compound 2D structures were sketched and con-
verted to a 3D format. The 3D geometry of structures
was cleaned and optimized to attain stable conformations
with minimum energy. Figure 2 shows the chemical 2D
structures of all compounds drawn using MarvinSketch
6.1.0 (Marvin Calculator Plugin and Chemical Terms
Demo ChemAxon).
2.5. Protein–ligand docking
In order to explore the likely binding modes of the CPs,
chalcones, isoquinolenes, thiosemicarbazones onto the
substrate pocket of FP-2 and FP-3, the modelled 3D
homologues and crystal structures of human cathepsins,
molecular docking was performed using AutoDock4.2
(Morris et al., 2009). Prior to docking, identical chain
sequence information and cocrystallized water molecules
in protein crystal structures were deleted using DS.
AutoDock tools (ADT) were used to prepare the ligands,
protein structures and calculated models for the actual
modelling simulations. Using the Gasteiger–Hückel
method in ADT, the partial atomic charges of the ligands
were assigned. Cubic grid points were set at 70, 70 and
65 along the x, y and z directions, respectively, for all
the ligands with a grid spacing of .3472 Å. A centroid
point was generated on the catalytic Cys42 of FP-2 and
corresponding positions in all homologues. The grid box
spanned an area of residues around a 12 Å radius. Dock-
ing simulations were carried out locally on a Linux-
based cluster with the parameters set as follows: genetic
algorithm (GA) and the Lamarckian genetic algorithm
variant were used for receptor–ligand conformational
search. The population size was set at 150, 100 GA runs,
maximum energy evaluations of 450,000 and maximum
number of generations set at 27,000. Cluster analysis for
docked results was done using a root mean square
(RMS) tolerance of 2.0 Å. Ligands in the best predicted
poses were visually analysed to identify interactions of
speciﬁc interest using DS. An energy heat map was cre-
ated using the gnuplot program (Gnuplot (4.6.6) [Com-
puter software], http://gnuplot.sourceforge.net/). An ad
hoc Perl script utilizing LigPlot+ subroutines (Laskowski
& Swindells, 2011) was used to determine the hydrogen
bonding and hydrophobic interactions between each
ligand and active-site residues. From the docking results,
protein–compound complexes with low-docking energy
scores were selected for the molecular dynamics and
BFE calculations.
2.6. Molecular dynamics simulations
To determine the stability and map the intermolecular
interactions of CPs with the cysteine proteases, molecu-
lar dynamics (MD) simulations of up to 10 nanoseconds
(ns) were performed using GROMACS 4.5.5 package
(Pronk et al., 2013) with AMBER96 force ﬁeld
(Kollman, 1996). The protonation state of all the pro-
tein’s ionisable amino acid groups at a pH of 5.0 were
assigned using the DS protein utility module, and proto-
nation was performed accordingly with the pdb2gmx
functionality of GROMACS to mimic the acidic environ-
ment of the lysosomal vacuole where the proteins reside
(Hogg et al., 2006). Ligand topology ﬁles were
generated using ACPYPE interface (Sousa da Silva &
Vranken, 2012) and Open Babel (O’Boyle et al., 2011).
The protein–CP complexes were solvated in a triclinic
box of dimension 17.5 Å and the ﬂexible SPC water
model was used to create an explicit continuous water
model. The system was neutralized to a total charge of
zero by randomly replacing water molecules with .15 M
counter ions (Na+ and Cl-). To avoid high-energy interac-
tions and steric clashes, the system was subjected to a
steepest descent energy minimization process without
constraints until a tolerance of 1000 kJ mol−1 nm−1 was
obtained. Each energy minimized system was then
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equilibrated in the canonical ensemble (for 200 ps
through the NVT ensemble set at 300 K) and subse-
quently in the isothermal-isobaric ensemble (for 200 ps).
The NPT conditions were set at 1.0 bar of pressure in all
directions and a pressure coupling constant (τP) of 2.0 ps
using the V-rescale thermostat (Bussi, Donadio, &
Parrinello, 2007) and the Parrinello-Rahman barostat
(Parrinello, 1981) algorithms, respectively. The values of
the isothermal compressibility were set at 4.5 ×
10−5 bar−1 for water simulations. The pre-equilibrated
systems were thereafter subjected to a 10 ns production
run with an integration time step of 2 femtoseconds (fs)
while maintaining temperature and pressure. All bond
lengths during equilibration and production runs were
constrained utilizing the LINCS algorithm (Hess, Bekker,
Berendsen, & Fraaije, 1997). Long-range electrostatic
interactions were approximated by the particle-mesh
Ewald algorithm (Petersen, 1995) with a .16 nm Fourier
grid spacing and a fourth-order interpolation, while the
cut-off distances for the calculation of Coulomb and van
der Waal interactions were set at 1.4 nm. During the
sampling process, trajectory snapshots were stored at
every 2 ps for structural analysis.
MD trajectories were analysed using the GROMACS
in house tools in conjunction with LigPlot+. In house ad
hoc Perl and Python scripts were used to automate the
analysis process. Xmgrace of Grace 5.1.21 was used to
plot MD graphical displays, while protein–ligand
complex visualizations were performed using PyMOL
software (The PyMOL Molecular Graphics System,
Version 1.6.0.0 Schrödinger, LLC.)
2.7. BFE calculations
According to the molecular mechanics/Poisson–
Boltzmann surface area (MM-PBSA), the strength of
interactions between the different protease–CP complexes
(total BFE) was determined using g_mmpbsa tool
(Kumari, Kumar, & Lynn, 2014). Using the single trajec-
tory approach, the calculations were performed on 4000
snapshot structures extracted at 2 ps intervals over the last
8 ns of each of the system’s GROMACS generated
trajectories. The following set of equations was used to
calculate the BFE:
DGbind ¼ Gcomplex  ðGreceptor þ GligandÞ (1)
DGbind ¼ Egas þ Gsol  TDS (2)
Egas ¼ Eint þ Evdw þ Eele (3)
Gsolv ¼ Gpol þ GsA (4)
GSA ¼ cSASA þ b (5)
where Gcomplex, Greceptor and Gligand denote the absolute
free energy of the protein–ligand complex, apoprotein
and ligand, respectively. Egas, Eint, Evdw and Eele signify
Figure 2. 2-D structures of the different sets of non-peptidic compounds used in this study.
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gas-phase, internal, van der Waals and electrostatic ener-
gies in that order. The solvation-free energy (Gsolv) is
composed of polar (Gpol) and non-polar (GSA) terms: the
former is estimated from a solution of the linear Pois-
son–Boltzmann (PB) equation, and the latter from the
solvent accessible surface area (SASA) using a water
probe of radius 1.4 Å, an offset value (b) of
3.84928 kJ mol−1 and surface tension proportionality (γ)
set at .0226778 kJ mol−1 Å−2. T and S correspond to
temperature and solute entropy, respectively. To decipher
key determinants involved in the ligand-binding process,
the BFE energetic contributions by van der Waals forces,
electrostatic energy, as well as polar and non-polar solva-
tion energy were decomposed for each the protein–ligand
complex systems. A per-residue decomposition analysis
of the contribution of each protein residues to the three
components of BFE was also calculated.
2.8. System speciﬁcations
Unless otherwise stated, all the computational analysis
including 3D model building and MSA were performed
on a Linux Intel Xeon workstation equipped with four
3.10 GHz parallel E3-1220V2 processors, Quadro K600/
PCIe/SSE2 graphics card and 31.1 GB RAM. Molecular
dynamics and binding BFE calculations were performed
using a local cluster, and the Tsessebe cluster (Sun)
high-performance computing unit at the CHPC (Centre
for High Performance Computing, n.d.), Cape Town,
South Africa. All webservers and databases used for
data-set retrieval and analysis are listed in Supplementary
Table S1.
3. Results and discussion
3.1. Sequence analysis
Besides the protein sequences of FP-2 and FP-3, seven
plasmodial and three human homologues were retrieved
from PlasmoDB and NCBI databases (Table 1). That is,
the retrieved protein sequences were all FP-2 and FP-3
orthologues was strongly supported by the reverse
BLAST results. Interestingly, in most of the reverse
BLAST results, the ﬁrst hit was to FP-3 rather than FP-
2, even though the initial BLAST search was performed
with FP-2 as query sequence, indicating that some of the
homologue proteins are not accurately annotated in the
literature.
MAFFT MSA output after additional minor manual
adjustments was considered to be the best for the cat-
alytic domain. Sequence identities (SI) were calculated
(Table 1) and conservation of protein sequence features
were determined (Figure 3(a)). From the primary
sequence alignment, 45 aa positions (highlighted in
green) inclusive of the clan C1A characteristic catalytic
triad residues, namely Cys, His and Asn (marked with
an asterisk) and the Gly-Cys-X-Gly-Gly motif, were
fully conserved in all protein sequences. In addition, up
to 18 aa positions were only conserved in the plasmodial
proteases (highlighted in blue), whereas 23 aa positions
were unique in the human cathepsins (highlighted in
black). Up to 34 aa positions were conserved exclusively
in the rodent plasmodial proteases (highlighted in grey).
Four aa positions were conserved only in the human
plasmodial proteases (highlighted in red). Two clearly
visible amino acid inserts present only in the plasmodial
proteases were observed, one at the N-terminal and the
other near the C-terminal (boxed). The ﬁrst insert of
about 17 residues (commonly referred to as nose) has
been shown to be important for the correct folding of the
catalytic domains of FP-2 and FP-3 before assuming its
ﬁnal active conformation (Pandey & Dixit, 2012). The
second insert consisting of approximately 14 aa (com-
monly referred as arm) structurally forms a highly ﬂexi-
ble β-hairpin. Wang et al., associated it with the
haemoglobin (substrate) binding process (Wang et al.,
2007). Both in FP-2 and FP-3, the arm is fairly con-
served, while in the rest of the plasmodial orthologues,
variations were observed. Although it is yet to be deter-
mined, it can be assumed that the inserts play similar
functions in the other plasmodial homologues as estab-
lished in FP-2 and FP-3. Interestingly, the rodent plas-
modial proteases had a unique aa pattern at the arm
region compared to the human plasmodial forms.
Besides the catalytic cysteine residue, all plasmodial pro-
teases had a total of eight cysteine residues in the cat-
alytic domain which form a set of four disulphide bonds.
In contrast, the human cathepsins had only six extra cys-
teine residues capable of forming three sets of disulphide
bonds.
A characteristic feature of cysteine proteases is the
presence of an active-site pocket constituted by residues
surrounding the catalytic triad. It is situated in a cleft
between the structurally conserved R and L domains and
consists of subsite S1, S2, S3 and S1’ (Kerr, Lee, Pandey
et al., 2009). By comparing the active-site pockets of
human cathepsins and plasmodial cysteine proteases, the
structural information that controls the selectivity and
functioning of these proteins can be determined, a key
feature in designing efﬁcacious and more potent drugs.
As shown in Figure (3(b)), it was observed that S1 and
S3 subsite residues are fairly conserved, while S2 as well
as a signiﬁcant number of aa positions in S1′ are highly
varied. Although at the sequence level the effect of these
observations on the structure and functions of the pro-
teins cannot be determined, it is well known that S2
plays a key role in the speciﬁcity of ligand binding
(Pandey & Dixit, 2012). Amino acid residues Gln36
(S1), Asn173 (S2) and Asn204 (S1’), which are key in
polarizing His174 (S1’) during catalysis, are conserved
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in all proteases with an exception of the S2 position of
Cat L which has Asp residue (numbering as per FP-2
catalytic domain). In S1, the two conserved cysteine resi-
dues (Cys39 and Cys80) form one of the four disulphide
bridges critical in stabilizing the proteins (Hogg et al.,
2006). The small polar Gly40 residue is conserved in all
homologues except in the rodent associated proteases
where it is replaced with a biochemically related
non-polar alanine residue. Even though the ﬁfth position
of S1 was highly varied among the proteases, residues
occupying this position were all polar suggesting a con-
served function. S2, which has been deﬁned as the major
pocket that determines ligand speciﬁcity in cysteine pro-
teases, was mainly occupied by hydrophobic residues as
per previous observation (Pandey & Dixit, 2012). A
striking difference between the human plasmodial homo-
logues and the rest including the cathepsins is the pres-
ence of a polar charged residue at the S2 pocket’s
hollow end of human plasmodial proteases, while the
rest have a small uncharged residue at the same position.
Zhao et al., observed that the S2 of human Cat K was
constituted by hydrophobic residues, but from our
results, this was the case only with Cat L and Cat S
(Zhao et al., 1997). S2 pocket volume of FP-2 vis-à vis
FP-3 and VP-2 vis-à-vis VP-3 have been shown to vary
in size indicating that careful consideration of the size
and shape of inhibitor groups targeting this site have to
be carefully determined. FP-2 has less bulky Leu84 and
Leu172 at the S2 opening groove while in FP-3, these
residues are replaced with more bulky Tyr86 and Pro174
resulting in a narrower distal end (Sabnis, Desai, Rosen-
thal, & Avery, 2003). In VP-3, the area between S1′ and
S2 subsites is folded inwards making the S2 narrower
than in VP-2 (Desai & Avery, 2004). In the rodent
plasmodial proteases, the S2 opening residues are highly
conserved with less bulky Ile85 and Ala173 on either side.
It was observed that S3 has a rich highly conserved
glycine component, a feature that provides additional
protease-substrate stability via hydrogen bonding (Desai
& Avery, 2004). At the opening of the V-shaped cleft,
there exists a highly conserved tryptophan residue in all
the proteases, which has been found to form hydrophobic
interaction with substrates (Sabnis et al., 2003).
3.2. Homology modelling and quality validation
Seven high-quality protein models of the catalytic (ma-
ture) domains of Plasmodium FP-2 and FP-3 homo-
logues, VP-2 (Vivapain-2), VP-3 (Vivapain-3), BP-2
(Berghepain-2), CP-2 (Chaubapain-2), KP-2 (Knowlesi-
pain-2), KP-3 (Knowlesipain-3) and YP-2 (Yoelipain-2)
were calculated using MODELLER version 9.10. The
position of the catalytic domain for each of the FP
homologues in the whole sequence and the adopted cat-
alytic domain numbering is shown in Table 1. For each
of these proteins modelled, two templates (PDB IDs:
2OUL and 3BWK) were consistently identiﬁed from
HHpred web server (Supplementary Table S2). To attain
alignment accuracy, the secondary structure prediction in
the HHpred alignments were considered, and HHPred,
PROMALS3D and MAFFT alignments were compared;
if necessary hand adjustments were done (Figure 3(a)).
The suitability of the obtained templates was scrutinized
by assessing the target sequence coverage and resolution.
Furthermore, template quality assessment results by
MetaMQAPΙΙ, ANOLEA and Ramachandran plot
showed that the two selected templates were suitable.
Depending on the sequence identity score, KP-2 was
modelled using 3BWK, while BP-2, CP-2, YP-2 used
2OUL and the rest used both templates. All resulting 3D
models were assessed by discrete optimized potential
energy (DOPE)-Z score, global distant test-total score
Table 1. A summary of FP-2 and FP-3 homologues from different Plasmodium species and Homo sapiens.
Accession number
Common name
(abbreviation)
Source organism
(abbreviation)
% SI
Position in whole
sequence
Catalytic domain
numberingFP-2 FP-3
PF3D7_1115700 Falcipain-2 (FP-2)§ P. falciparum (Pf) 100 66 244–484 1–243
PF3D7_1115400 Falcipain-3 (FP-3)§ 66 100 250–492 1–249
PVX_091415 Vivapain-2 (VP-2) P. vivax (Pv) 62 66 246–487 1–242
PVX_091410 Vivapain-3 (VP-3) 57 57 253–493 1–241
PCHAS_091190 Chaubapain-2* (CP-2) P. chabaudi (Pc) 50 48 231–471 1–241
PKH_091250 Knowlesipain-2* (KP-2) P. knowlesi (Pk) 57 57 252–495 1–244
PVX-091260 Knowlesipain-3* (KP-3) 57 60 240–479 1–240
PBANKA_093240 Berghepain-2* (BP-2) P. berghei (Pb) 51 47 228–468 1–241
PY00783 Yoelipain-2* (YP-2) P. yoelii (Py) 48 47 232–472 1–241
gi | 157830076 Cathepsin-K (Cat K) H. sapiens (Hs) 38 41 115–329 1–215
gi | 313754424 Cathepsin-L (Cat L) 37 38 113–333 1–221
gi | 30749675 Cathepsin-S (Cat S) 36 37 115–331 1–217
Notes: Marked with § indicates the query sequences while * indicates sequences renamed for convenience. % SI (Percentage Sequence Identity) is
based on the catalytic domain of FP-2 and FP-3.
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(GDT-TS) score as well as by the same programs used
for template quality check. From Supplementary
Table S2, KP-3 had the best normalized DOPE-Z and
GDT-TS scores. Shen and Sali estimated that DOPE
Z-score below −.5 are indicators of a protein structure
near to the native form, as such it is evident that all
Figure 3. Sequence analysis and subsite amino acid composition of FP-2, FP-3 and homologues. (a) MAFFT multiple sequences
output of FP-2/3 and homologues showing conservation of functional and structural residues. The Clan CA characteristic catalytic
triad residues are indicated with an asterisk. The two unique inserts in all plasmodial proteases are indicated with a black dashed box.
(b) Summary of the amino acid composition (table) and conservation (sequence logo) of all four subsites for FP-2/3 and homologues
as determined by WebLogo. The relative height of each letter and total height indicates the relative frequency of corresponding aa
and information content respectfully per site in all the sequences.
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models generated were of high quality (Shen & Sali,
2006). The colour code presentation of MetaMQAPΙΙ
results indicated that they had been accurately modelled,
except for some loop regions in some cases (blue for
accurate regions and red for problematic regions) as
shown in Supplementary Figure S1. Overall, the obtained
evaluation results indicated that the models are of high
quality, especially in the active site region, and can be
used for inhibitor-docking experiments.
3.3. Docking studies
A total of 20 non-peptide inhibitors of the chemical
classes of isoquinolines, chalcones, thiosemicarbazones
and CPs were docked to 12 cysteine proteases. Out of
these 12, three were human cysteine proteases, namely
Cat L, Cat S and Cat K. They were used to assess pro-
tein–ligand interaction characteristics that could provide
signiﬁcant information with regard to selectivity. Two
were crystal structures of FP-2 and FP-3 (2OUL and
3BWK, respectively) and the remaining seven proteins
were the 3D models of FP-2 and FP-3 Plasmodium
homologues. The results are presented in Figure 4 and
Table 2. The CP series of compounds exhibited the
lowest docking free energy of binding (strong afﬁnity)
and lowest inhibition constants against almost all
proteins compared to the other classes of compounds
used, and thus were selected for the subsequent steps of
MD simulations and BFE calculations.
In Table 2, thiosemicarbazones had high free energy
of binding which implied lower estimated binding afﬁni-
ties, and consequently, higher inhibition constants. Auto-
Dock inhibition constants of these compounds onto FP-2
were comparable with results obtained from experimental
enzyme assays (Chiyanzu et al., 2003; Greenbaum et al.,
2004; Liu et al., 2001). In both approaches, inhibition
constants were at μM levels, although in some cases the
experimental values were half or even a third of the
docking values. Docking results were varied between
2.13 and 24.99 μM. Chalcones showed the same trend as
thiosemicarbazones both in in silico results and experi-
mental data (Li et al., 1995). The two docked isoquino-
line derivatives showed varied binding afﬁnity.
Isoquinoline-A had considerably good docking free ener-
gies against all proteins compared to thiosemicarbazones
and chalcones. Interestingly, while assay results were
indicating inhibition at 3 μM against FP-2 for both
compounds (Batra et al., 2003), the in silico result for
isoquinoline-B agreed, but the isoquinoline-A was 10-
fold less. In fact, isoquinoline-A was good in the context
of Plasmodium homologues, with estimated inhibition
constants in the nanomolar range. Even though its
Figure 4. A heatmap showing the interaction free energies of all compounds when docked against plasmodial cysteine proteases
and human cathepsins using AutoDock4.2. The energy code ranges from high (yellow) to low (black).
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uniform docking free energy among Plasmodium pro-
teins and the human cathepsins raises concerns of selec-
tivity, it could be used as a starting scaffold for further
studies involving chemical modiﬁcations leading to
derivatives with increased potency and safety proﬁles.
Among the CPs, compound CPG, CPH and CPI had
the lowest inhibition constants as determined by Auto-
Dock (See Table 2) and had interaction energies ranging
between, −8 and −10 kcal mol−1 across all homologues
(Figure 4). According to docking results, these inhibitors
had high binding afﬁnity for FP-3 than FP-2. The esti-
mated inhibition constants were all in the nanomolar
range. Interestingly, experimental inhibition constants for
CPA-CPC for FP-2 and FP-3 were much lower than the
in silico results (Coterón et al., 2010). Compounds with
a cyclohexyl or cyclopentyl at the P2 position (corre-
sponds to S2 in protease) and pyridinyl–phenyl combina-
tions yielded antiparasitic activity at subnanomolar and
nanomolar levels against FP-2 and FP-3, respectively
(Coterón et al., 2010). According to Table 2, CPs are
better inhibitors against FP-3, VP-2 and KP-3 as com-
pared to FP-2, VP-3 and KP-2, respectively. In the case
of vivapains, Desai et al.,(Desai & Avery, 2004)
observed that VP-2 was more sensitive to inhibitors than
VP-3 as its S2 opening was wider. In contrast, the other
classes of inhibitors seemed to inhibit FP-2 more than
FP-3. The activity of CPs seemed to be largely inﬂu-
enced by the chemical composition of R1 and R2
(Figure 2). Compound CPG, CPH and CPI were the
strongest binders against all proteases (see Figure 4 and
Table 2). Interestingly, R1 group that was the same in
CPA-CPC, CPD-CPF and CPG-CPI seemed to affect the
overall docking energy score in the human cathepsins
and falcipains. CPs had a cyclopentyl or cyclohexyl at
R2 which bound at or near the S2 position. Compounds
CPC, CPF and CPI which had a cyclohexyl group at R2
exhibited lower docking energies and inhibition constants
when in complex with most proteins. This was depen-
dent on whether the opening of S2 was wide enough to
allow the entry of the R2 group. Rosenthal et al.,
(Rosenthal, Wollish, Palmer, & Rasnick, 1991) previ-
ously established that the S2 of FP-2 preferred the phe-
nyl group of phenylalanine, a group that is chemically
similar to the cyclohexyl. Additionally, the binding poses
of CPs varied in different proteins as seen in Figure 5,
for example for CPG, CPH and CPI, thus explaining the
differential docking energies and inhibition constants in
Figure 4 and Table 2. In Cat K (Figure 5(a)), CPG ﬁts in
well interacting with most subsite residues as compared
to CPH and CPI, hence the resulting low docking energy
and inhibition constant. In Cat L, the three compounds
have similar pose resulting in almost similar inhibition
constants (Figure 5(b)). For FP-2 and FP-3, the gate to
S2 seems to play a key role in determining what goes in.
In FP-2, the compounds can access and thus interact
with S2 subsite residues (Figure 5(c)), while in FP-3, the
Table 2. AutoDock inhibition constants (μM) of the CPs onto FP-2 and FP-3 and homologues. Enclosed in brackets are the IC50
from wet laboratory assays. The references for the assays were given in the main text.
Protein
Plasmodial Human homologues
CMPD FP-2 FP-3 VP-2 VP-3 KP-2 KP-3 BP-2 CP-2 YP-2 Cat S Cat L Cat K
CPA .80 (.0005) .33 (.006) .14 3.32 2.51 .45 .38 .54 1.02 1.68 2.09 .24
CPB .78 (<.0005) .11 (.011) .52 3.14 2.71 .18 .39 .85 3.42 3.19 2.27 .43
CPC .53 (.0005) .12 (.006) .12 1.61 1.22 .21 .34 .36 .50 .71 .79 .13
CPD 1.23 .35 .46 2.63 1.06 .36 .58 .32 .13 6.80 .32 1.08
CPE 1.62 .27 .72 1.91 1.35 .48 .38 .47 .82 11.16 .36 1.14
CPF 1.58 .29 .36 2.34 1.91 .20 .94 .81 1.68 12.19 .31 .94
CPG .16 .03 .02 .81 .11 .04 .05 .16 .04 .27 .14 .10
CPH .08 .01 .01 .25 .06 .02 .01 .04 .04 .16 .06 .13
CPI .08 .01 .01 .06 .02 .02 .03 .03 .02 .22 .03 .15
CL-A 1.63 3.50 9.03 2.98 2.25 1.60 4.10 2.82 6.10 14.95 5.02 2.36
CL-B 15.64 22.94 4.18 28.42 8.58 18.86 12.27 6.60 10.26 7.20 21.99 12.36
CL-C 3.57 (1.80) 2.08 1.53 8.62 4.60 7.85 2.45 2.94 1.52 7.18 6.31 .92
IQ-A .34 (3.00) .58 .34 .63 .85 .60 .17 .08 .37 .33 .54 .24
IQ-B 3.41 (3.00) 5.41 3.55 5.75 4.02 5.84 2.50 3.73 4.45 4.66 5.88 1.67
TSC-A 24.99 40.27 15.17 42.72 26.92 18.64 14.00 12.67 14.11 33.75 26.48 22.12
TSC-B 5.25 (4.40) 10.79 11.14 10.51 14.58 6.45 23.34 19.48 15.47 12.58 9.35 19.20
TSC-C 20.28 (10.00) 35.73 14.57 87.47 33.82 35.30 22.57 27.24 31.24 36.38 14.69 30.51
TSC-D 12.72 (5.80) 45.65 13.09 48.25 30.33 14.39 13.83 42.55 24.61 42.84 5.88 62.04
TSC-E 9.84 (3.80) 40.69 15.66 43.92 10.84 8.54 19.89 12.99 16.43 52.21 13.66 37.77
TSC-F 2.13 (2.25) 2.13 1.87 1.85 2.29 3.75 .21 .29 .87 3.97 1.72 3.60
Note: CMPD = Compound, CPX = 2-cyanopyrimidine, CL = Chalcone, IQ = Isoquinolene, TSC = Thiosemicarbazone.
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narrower gate hinders their entry (Figure 5(d)). Despite
this observation, FP-3 has lower docking energies and
inhibition constants. A similar observation is made in the
case of VP-2 and VP-3 (Figure 5(e) and (f)). In the case
of knowlesipains, the compounds interacted mainly with
S2 residues (Figure 5(g) and (h)). A comparison to a
recent study using novel artemisinin derivatives as FP-2
inhibitors by Liu et al., shows that the aa interactions
pattern between CPG, CPH and CPI and FP-2 and FP-3
were similar (Liu et al., 2012).
3.4. Stability of protein–ligand (CP) complexes
10 ns all-atom MD simulation of each of the proteases in
complex with the CP derivatives was performed to
obtain a dynamical picture of the conformational changes
as a function of time. For quality assurance, the conver-
gence of thermodynamic parameters namely temperature,
total and potential energies was performed beforehand
(data not shown). To determine if the simulated protein–
ligand system formed stable complexes, the root mean
square deviation (RMSD), a global measure of confor-
mational diversity, the radius of gyration (Rg), a measure
of compactness and the root mean square ﬂuctuation
(RMSF), a local measure of conformational diversity rel-
ative to the initial structures, were monitored. Using an
in house Perl script, the mean and standard deviations of
RMSD for the apo structures, CPs and protein–CP com-
plexes as well as the Rg during the last 6 ns of MD sim-
ulations were determined. In the ﬁrst 2 ns, the RMSD
values increased after which they converged.
From Figure (6(a)), resulting RMSD values of all
apo structures used in this study indicated that they were
quite stable based on the error bars. In Figure (6(b)), the
human cathepsins-CPs attained RMSD values ranging
from .15 to .19 nm with standard deviations of up to
.02 nm, while the plasmodial–CPs complexes had
RMSD values ranging from .18 up to .29 nm. The little
ﬂuctuations as depicted by the standard deviations sug-
gested that the complexes were stable and snapshots of
structures at different times could be collected for further
analysis. The effect of a ligand is either to stabilize or to
destabilize a receptor upon binding and thus considering
the small size of CPs compared to the respective proteins
used in this study and the resultant RMSD values (Fig-
ure 6(c)), all CPs compounds seemed to stabilize the sys-
tems. As seen from Figure (6(d), during the simulation,
all structures were compact. From the RMSF plots
(Supplementary Figure S2), the plasmodial proteases
(falcipains and vivapains) exhibited huge local confor-
mational diversity within the β-hairpin (~aa 175–aa 200),
an inimitable structure associated with the binding of
haemoglobin (Hb) (Hogg et al., 2006). This observation
was consistent with the other plasmodial proteases (Data
not shown). In contrast, the human cathepsins (Cat K
and Cat L) exhibited minimal RMSF ﬂuctuations, a fact
Figure 5. Binding modes of CPG, CPH and CPI compounds in the binding pocket of human cathepsins and plasmodial homo-
logues. Surface view of the orientation of CPG (blue), CPH (magenta) and CPI (green) on the S1 (pale yellow), S2 (cyan), S3
(brick-red) and S1’ (orange) of (a) Cat K, (b) Cat L, (c) FP-2, (d) FP-3), (e) VP-2, (f) VP-3, (g) KP-2) and (h) KP-3.
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Figure 6. Stability of protein–CPs complexes as determined by GROMACS tools during the last 6 ns of MD simulations. Graphs
showing the mean values of RMSD for apo structures (a), protein–ligand complexes (b), ligands only (c) and the radius of gyration
for protein–ligand complexes (d). Error bars show the standard deviations.
Figure 7. Conformational changes of CPG within active-site pockets (a) Cat K and (b) FP-2 during MD simulations. The brick red
surface shows the S1′ position. The corresponding panels on the right show the residues interacting with CPG in Cat K and FP-2 at
10 ns, respectively. The selected regions show the different subsites that constitute the binding pocket. Yellow dashes represent hydro-
gen bonds between heavy atoms.
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linked to the much shorter arm region. All other residues
showing huge ﬂuctuations were located on loop regions.
As these ﬂuctuations were not occurring in the active
site, it can be concluded that the protein–ligand complex
system remained stable during the simulation period.
Structure visualization using PyMOL showed the ligands
ﬁtted well onto the binding pockets and their stabiliza-
tion was facilitated mostly by a network of hydrophobic
and hydrogen bonding between the ligand’s atoms and
residues lining the S1, S2 S3 and S1′ subsites.
3.5. Structural chemical features of binding
Several interactions between the residues lining the active
pocket subsites and the ligand play key role in stabilizing
it depending on the chemical group and nature of the sur-
rounding environment. To extract the aa–ligand-binding
footprint along the MD simulations for all generated 3D
structures, a Perl script with LigPlot + batch processing
functionality was used. Supplementary Table S4 shows
the number and individual aa involved in van der Waals
interactions and hydrogen bonds, respectively. Notably,
from these interaction results, the number of van der
Waals and hydrogen interactions between CPD, CPE and
CPF and protein residues were drastically fewer compared
to when the proteins were interacting with the rest of CPs,
an observation that could be explained by their observed
binding modes and the short length of R1. In contrast,
CPG, CPH and CPI maintained van der Waals interactions
with most subsite aa residues mainly because of the
extended chemical nature of R1. Figure 7 illustrates the
conformational changes of compound CPG in complex
with Cat K (Figure 7(a)) and FP-2 (Figure 7(b)) during
MD simulations.
From these results, CPG attains a stable conformation
all through from 6 ns with the R1 chemical group stably
interacting with S1′. These results were observed in the
other proteins when in complex with CPG-CPI. Shown
also in Figure 7 are the zoomed view of the key subsite
residues in Cat K and FP-2 interacting with CPG
through van der Waals and hydrogen interactions. In
both cases, it is evident that CPG interacted with most
subsite S1′ residues.
3.6. BFE analysis
To obtain the predicted BFE and the energetic
contributions of van der Waals (vdW), electrostatic (ele)
interactions, polar solvation (PB) and entropy (SASA),
MM-PBSA method was used. Table 3 shows a summary
of the overall BFE underlying the binding of CPs to
FP-2 and FP-3 as well as their homologues. From the
Table 3. Protein–CP complexes overall BFE (ΔGbind) in kJ mol
−1 as determined by g_mmpbsa tool.
Compound
Protein CPA CPB CPC CPD CPE CPF CPG CPH CPI
FP-2 −84.9 ± .2 −71.8 ± .3 −80.8 ± .2 −91.1 ± 2.7 −93.1 ± .2 −80.5 ± .2 −131.5 ± .2 −103.4 ± .2 −99.6 ± .2
FP-3 −77.0 ± .2 −67.1 ± .2 −66.7 ± .2 −74.2 ± .2 −74.7 ± .2 −102.8 ± .4 −87.6 ± .2 −111.7 ± .2 −105.7 ± .3
VP-2 −95.0 ± .2 −78.7 ± .2 −60.6 ± .2 −85.8 ± .2 −72.4 ± .6 −77.7 ± .3 −116.2 ± .3 −81.8 ± .2 −93.0 ± .2
VP-3 −112.4 ± .2 −72.6 ± .2 −59.0 ± .5 −98.6 ± .3 −55.0 ± .2 −62.1 ± .3 −104.8 ± .2 −93.7 ± .2 −85.7 ± .2
PK-2 −115.5 ± .3 −68.8 ± .3 −68.8 ± .4 −92.8 ± .3 −99.0 ± .2 −85.7 ± .3 −129.2 ± .2 −61.9 ± .3 −86.8 ± .2
PK-3 −80.3 ± .4 −63.0 ± .2 −81.7 ± .3 −82.1 ± .2 −80.4 ± .2 −80.9 ± .2 −68.5 ± .3 −76.2 ± .3 −80.9 ± .3
BP-2 −92.9 ± .2 −92.1 ± .4 −82.8 ± .4 −133.3 ± .5 −80.5 ± .5 −85.0 ± .3 −135.4 ± .4 −131.7 ± .3 −94.9 ± .3
CP-2 −73.0 ± .2 −85.4 ± .2 −71.9 ± .1 −108.3 ± .3 −122.6 ± .3 −83.7 ± .3 −103.9 ± .4 −103.4 ± .3 −98.1 ± .3
YP-2 −91.6 ± .3 −67.0 ± .3 −82.1 ± .2 −103.0 ± .2 −114.6 ± .3 −89.1 ± .3 −92.3 ± .2 −104.8 ± .2 −97.8 ± .3
Cat S −97.7 ± .2 −72.2 ± .2 −83.9 ± .3 −85.8 ± .3 −85.6 ± .2 −84.9 ± .3 −93.8 ± .3 −98.2 ± .3 −81.8 ± .3
Cat K −86.4 ± .3 −91.3 ± .2 −93.6 ± .2 −90.8 ± .3 −104.1 ± .2 −76.6 ± .3 −96.3 ± .3 −80.0 ± .2 −81.8 ± .2
Cat L −132.4 ± .3 −99.2 ± .2 −44.7 ± .5 −129.2 ± .3 −117.5 ± .2 −111.8 ± .3 −117.3 ± .3 −149.7 ± .3 −147.6 ± .2
Figure 8. Subsite amino acid contributions to BFE for com-
pound CPG, CPH and CPI.
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results, it was noted that in most cases, CPG, CPH and
CPI had the lowest binding energies, an indication of
stronger interactions compared to the other CPs. This
was in agreement with the docking results as the same
ligands had the lowest docking energies. From the differ-
ent energetic contributions (Supplementary Table S5), it
is evident that the binding process was principally
favoured by van der Waals and electrostatic terms while
the polar solvation impaired it. Surprisingly, the non-po-
lar solvation energies which correspond to the burial of
SASA upon binding contributed slightly in equal order
to the binding process in all complexes. To determine
the key amino acid residues determining the strength of
interactions in each of the protein–CP complexes, the
ﬁnal BFE was further decomposed into individual resi-
due contributions. For compounds CPG, CPH and CPI,
the sum total energy contribution of residues lining the
four individual subsites was calculated. As seen from
Figure 8, S1′ subsite residues contributed to negative
energy scores for the complexes of the three ligands and
all proteases used in the study. However, S1–S3 had sig-
niﬁcant varying net energies (positive or negative) for
the different ligands. For the binding of CPG, CPH and
CPI to FP-2, S1 and S3 residues entirely contributed to a
net positive energy as opposed to S2 and S1′ … S2 and
S3 residues contributed to negative energies for all non-
human plasmodial proteases in complex with the three
ligands (Figure 8(b) and (c)). This explains why Cat L
had lower BFE value for the three ligands compared to
Cat K. In the case of the plasmodial proteases binding,
hot spots were mainly found within the binding cleft
subsites. As seen in Figure (8(c)), S3 aa impaired bind-
ing of the ligands onto the plasmodial cysteine as
opposed to the human cathepsins. This information is
quite important in understanding the residues giving
attractive contributions to binding and should be consid-
ered during the rational drug design process of novel
plasmodial cysteine protease inhibitors with increased
selectivity towards the human proteases.
4. Conclusion
We report a comprehensive in silico approach encom-
passing several computational methods namely homol-
ogy modelling, molecular docking, MD simulations and
BFE calculations to determine the broad spectrum inhibi-
tory activity and selectivity of non-peptidic compounds
against FPs and their homologues from different Plas-
modium species and human cathepsins. Although the
compounds used in this study have been tested for activ-
ity mainly against FP-2 and FP-3 via wet laboratory
assays (Batra et al., 2003; Chipeleme et al., 2007;
Chiyanzu et al., 2003; Coterón et al., 2010; Domínguez
et al., 2005; Greenbaum et al., 2004; Kerr, Lee,
Faraday et al., 2009; Li et al., 1995; Liu et al., 2001;
Verissimo et al., 2008), to our knowledge this was the
ﬁrst attempt to report the broad spectrum inhibitory
activity of these compounds using in silico approaches
against FPs and their homologues. Through molecular
docking, MD simulations and BFE calculations, key
amino acids within the receptors’ active pocket responsi-
ble for the strong binding of the CPs ligands were
Figure 9. Per-residue decomposition ﬁngerprint of compound CPG, CPH and CPI in complex with (a) Cat K (b) Cat L (c) FP-2 (d)
FP-3 (e) VP-2 and (f) VP-3.
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deciphered. In all cases, van der Waals forces and polar
solvation energies were proposed as the main BFE terms
favouring and inhibiting the binding of CPs to the recep-
tors respectfully. CPs represents a class of non-peptidic
compounds with a broad spectrum activity against plas-
modial FP homologues. Although there was no clear cut
selectivity proﬁles of these compounds against human
cathepsins, previous pre-clinical studies involving cys-
teine protease inhibitors with little or no selectivity to
target trypanosomal and plasmodial parasites were toler-
ated in animal models. This can be linked to the fact that
the human cathepsins are present in elevated concentra-
tions compared to that of the parasite origin and the
redundant nature of the mammalian cysteine proteases
family (Ang et al., 2011). However, besides the beneﬁ-
cial intracellular housekeeping roles of human cathep-
sins, they can also be attractive targets for drug
discovery as they have been found to play speciﬁc roles
in antigen presentation, bone resorption and pro-hormone
activation, processes critical for the progression of a vari-
ety of disease states such as rheumatoid arthritis, osteo-
porosis and autoimmune maladies. Hence, this protocol
may also be valuable to the identiﬁcation of potential
inhibitors against the human cathepsins (Figure 9).
A 3D-QSAR study by Cátia et al., on peptidyl vinyl
sulfone derivatives as FP-2 inhibitors showed the major
structural requirements necessary for optimal activity
(Teixeira, Gomes, Couesnon, & Gomes, 2011). A similar
approach on non-peptidic heteroarynitrile derivatives by
Wang et al., led to comparable conclusions where differ-
ent subsite pockets preferred groups with certain chemi-
cal properties (Wang et al., 2013). A comparison of
these results to our docking, MD and BFE shows great
consistency. For example, from the per-residue energy
decomposition, key aa contributing to the BFE of F2-
CPI, a total of 10 residue including Asp35, Cys42,
Leu84, Val152, Ser153, Asp154, Asp155, Asn173,
His174 and Ala175 were identiﬁed in both cases as
important in the binding process. The consideration of
the important players (energetics and residues) in binding
of non-peptidic compounds to proteases of key human
Plasmodium species as well as the human cathepsins
presents unique results that can be exploited in the struc-
ture-based molecular guided design of more potent anti-
malarial drugs.
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